Gilead Sciences Inc. closed $6.85 short of its 52-week high ($98.90), which the company achieved on November 11th.

Gilead Sciences (GILD) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

For years, Gilead Sciences was dead money for shareholders. That is starting to change, and a recent rally in the stock can ...

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Cantor Fitzgerald reaffirmed their neutral rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a report ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...